## RECEIVED CENTRAL FAX CENTER

17328151330

77 Brant Avenue, Suite 110 Clark, New Jersey 07065 Telephone No. (732) 815-0404 Fax No. (732) 815-1330 SEP 0 6 2005





To:	USTPO -	From: Scott S. Servila
Fax:	571 273 8300	Pages: 3 (including cover)
Phone		Date: September 6, 2005
Re:	10/812,156	CC:
□ Urge	ent 🗆 For Review 🗆 l	Please Comment 🗆 Please Reply 🗆 Please Recycle

## • Comments:

Power of Attorney and 3.73b Statement re WEL0002-01CP

**CENTRAL FAX CENTER** 

SEP 0 6 2005

PTO/SB/80 (11-04)

Approved for use through 11/30/2005, OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information Unless it displays a valid OMB control number.

POWER OF ATTORNEY TO PROSECUTE APPLICATIONS BEFORE THE USPTO I hereby revoke all previous powers of attorney given in the application identified in the attached statement under 37 CFR 3.73(b) I hereby appoint: 48394 Practitioners associated with the Customer Number: Practitioner(s) named below (if more than ten patent practitioners are to be named, then a customer number must be used): Registration Name Registration Number Name Number as attorney(s) or agent(s) to represent the undersigned before the United States Patent and Trademark Office (USPTO) in connection with any and all patent applications assigned only to the undersigned according to the USPTO assignment records or assignment documents attached to this form in accordance with 37 CFR 3.73(b). Please change the correspondence address for the application Identified in the attached statement under 37 CFR 3.73(b) to: IXI The address associated with Customer Number: ORIndividual Name Address Zo City Country Fex Telephone Assignee Name and Address: InfaCare Pharmaceutical Corporation 600 West Germantown Pike Suite 400 Plymouth Meeting PA 19462 A copy of this form, together with a statement under 37 CFR 3.73(b) (Form PTO/SB/98 or equivalent) is required to be filed in each application in which this form is used. The statement under 37 CFR 3.73(b) may be completed by one of the practitioners appointed in this form if the appointed practitioner is authorized to act on behalf of the assignee, and must identify the application in which this Power of Attorney is to be filed. SIGNATURE of Assignee of Record individual whose signature and title is supplied below is authorized to act on behalf of the assignee Date 31 AVA Signature Telephone 108 koMu Name Stannsoporfin Compositions, Drug Products and Methods of Manufacture

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a behefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete the form and/or suggestions for reducing this burden, should be cent to the Chief Information Officer, u.s. Potent and Trademerk Office, U.S. Department of Commerce, P.O. Box 1450; Alexandria, VA. 22313-1450. D NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Paramete, P.O. Box 1450, Alexandria, VA/22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

## **BEST AVAILABLE COPY**

PTO/SB/96 (09-04)

Approved for use through 07/91/2008, OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE to a collection of information unless it displays a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no possens are required to respond to a construct of which	
STATEMENT UNDER 37 CFR 3.73(b)	
Applicant/Patent Owner. InfaCare Pharmaceutical Corporation	
Application No./Patent No.: 10/812,156 Filed/Issue Date: March 29, 2004	<u>-</u>
Entitled: PREPARATION OF METAL MESOPORPHYRIN HALIDE COMPOUNDS	·
Entitled: PREPARATION OF METAL NEGOF OR	
InfaCare Pharmaceutical Corporation . a Corporation (Type of Assignee, e.g., corporation, pa	rtnership, university, government agency, etc.)
states that it is:  1. It is assigned of the entire right, title, and interest; or	
2.  an assignee of less than the entire right, title and interest.  The extent (by percentage) of its ownership interest is%	
in the patent application/patent identified above by virtue of either:	
A An assignment from the inventor(s) of the patent application/patent identified about in the United States Patent and Trademark Office at Reel 16309, Frame thereof is attached.	
OR  B. A chain of title from the inventor(s), of the patent application/patent identified above below:	ve, to the current assignee as shown
To:	
1. From: The document was recorded in the United States Patent and Trademark C Reel, Frame, or for which a copy the	Office at ereof is attached.
2. From:To:	
From:     The document was recorded in the United States Patent and Trademark (     Reel, Frame, or for which a copy (	omce at thereof is attached.
3. From:To:To:	Office
3. From: The document was recorded in the United States Patent and Trademark ( Real, or for which a copy	onice at thereof is attached.
Additional documents in the chain of title are listed on a supplemental sheet.	
Copies of assignments or other documents in the chain of title are attached.  [NOTE: A separate copy (i.e., a true copy of the original assignment document(s))  Division in accordance with 37 CFR Part 3, if the assignment is to be recorded MPEP 302.08]	must be submitted to Assignment d in the records of the USPTO. <u>See</u>
The undersigned (whose title its supplied below) is authorized to act on behalf of the at	ssignee.
	Dotte Date
Signature	31 Avgust 2005 Date 610 200-1484
John R. Post Printed or Typed Name	Telephone Number
President Title	an a section

This collection of information is required by 37 OFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tredemark Office, U.S. Department of Commissioner for Patents, P.O. Box 1450, Alexandria, VA. 22313-1450. SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA. 22313-1450.

if you need assistance in completing the form, call 1-800-PTQ-9199 and select option 2.

## BEST AVAILABLE COPY